The asthma drug montelukast can counteract the changes made to the ocular system by diabetic retinopathy according to a new study published in Diabetes and carried out by researchers from the University Hospitals Rainbow Babies & Children’s Hospital and Case Western Reserve University.
Rose Gubitosi-Klug, the senior author of the study, explains as follows: “We found that montelukast (Singulair) was able to stop the signaling of inflammatory molecules called leukotrienes. This interruption significantly reduced the small blood vessels and nerve damage we see in the early stages of diabetic retinopathy.”
The discovery took place through experiments on mice and the fact that it is an already approved drug bodes well for a rapid progression of the phases that see experiments also on human subjects, as the scientist herself states.
Among other things, the daily dose used with mice during this study is similar to the one used to treat asthma.
In particular, this drug tends to prevent diabetic pathology and at the same time “avoids the complete inhibition of inflammation, which can compromise innate immunity,” as specified by Gubitosis-Klug.